Aarhus approves record-high apartment building

With 31 storeys, the 90-metre La Tour Tower will have 300 living units

Aarhus’s municipal council has approved the construction of a record-high residential building that will replace the old La Tour hotel on Randersvej, reports Jyllands-Posten.

The new 90-metre-tall La Tour Tower will become the city’s second tallest building, falling only a few metres short of Aarhus Cathedral.

The building, which has been designed by 3XN Architects, includes a five-storey semi-circular structure at the base of a 31-storey-tall tower, and in total it will include 300 living units.

If everything goes to plan, the construction work will begin this summer and the building will be finished within two years.

A nearby landmark water tower has been included in the design and will remain preserved as an important feature of the neighbourhood.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.